Advertisement NeuroVive, Sanofi enter commercialization deal for Ciclomulsion in South Korea - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

NeuroVive, Sanofi enter commercialization deal for Ciclomulsion in South Korea

NeuroVive Pharmaceutical Asia group has collaborated with Sanofi’s local affiliate for the development and commercialization of CicloMulsion in South Korea to treat reperfusion injury in cardiovascular disease.

As part of the deal, NeuroVive Asia will get an upfront payment, a conditional milestone payment and royalty on potential future sales in South Korea.

The deal will see Sanofi’s local affiliate responsible for regulatory processes and market approval, launch, marketing, distribution and sales of CicloMulsion in the country.

Prior to the product’s potential market launch, the NeuroVive group is conducting an extensive international program for the clinical development and commercialization of CicloMulsion.

NeuroVive CEO Mikael Brönnegård said: "The collaboration with Sanofi will enable us to broaden the commercialization of CicloMulsion for the treatment of cardiovascular disease.

"South Korea is an important market in Asia and this collaboration with Sanofi is further confirmation of CicloMulsion’s clinical and commercial potential.

"I look forward to a long and productive partnership with Sanofi, with the aim of launching CicloMulsion for the treatment of acute cardiovascular indications on the South Korean market."

Currently, CicloMulsion is being evaluated to treat reperfusion injury following myocardial infarct in a European clinical phase III study (the CIRCUS study).

CicloMulsion is also being evaluated to treat other acute heart and kidney injuries within the framework of the collaboration with Hospices Civils de Lyon and in a clinical Phase II trial in collaboration with Skåne University Hospital in Lund, Sweden.